“Post tuberculosis”: the urgent need for inclusion of lung health outcomes in tuberculosis treatment trials

Anthony Byrne 1,2, Brian Allwood 3, Ingrid Schoeman 4, James Johnston 5,6, Gautam Kalyatanda 7, Goodman Makanda 8, Kevin Mortimer 9, Carole Mitnick 10, Rebecca Nightingale 9, Obianuju Ozoh 11, Andrea Rachow 12 and Marieke Van Der Zalm 2,13

1St Vincent’s Health Australia, Heart Lung Clinic, Sydney, Australia. 2University of New South Wales, Sydney, Australia. 3University of Stellenbosch, Department of Medicine, Stellenbosch, South Africa. 4TB Proof, Director of Advocacy and Strategy, Pretoria, South Africa. 5British Columbia Centre for Disease Control, Vancouver, BC, Canada. 6University of British Columbia, Faculty of Medicine, Vancouver, BC, Canada. 7University of Florida, Department of Infectious Disease and Global Health, Gainesville, FL, USA. 8South African Medical Research Council, Tygerberg, South Africa. 9Liverpool School of Tropical Medicine, Respiratory Medicine, Liverpool, UK. 10Harvard University, Medical School and Department of Global Health and Social Medicine, Boston, MA, USA. 11University of Lagos, Department of Medicine, Lagos, Nigeria. 12LMU Munich, Division of Infectious Diseases and Tropical Medicine, Munich, Germany. 13Desmond Tutu TB Centre, Paediatrics and Child Health, Cape Town, South Africa.

Corresponding author: Anthony Byrne (Anthony.Byrne@svha.org.au)

Shareable abstract (@ERSpublications)

New TB treatment regimens are a welcome advancement. However, for the millions of TB survivors with impaired lung function and quality of life, more holistic outcome measures and the inclusion of lung function is essential in future TB treatment trials. https://bit.ly/3PWT0o2


This extracted version can be shared freely online.

To the Editor:

We read with interest the systematic review by Ivanova et al. [1], recently published in the European Respiratory Review, highlighting significant long-term lung function impairment experienced by people that survive tuberculosis (TB). Lung function impairment is a well-described characteristic of post-TB lung disease (PTLD), a condition that spans the spectrum of obstructive airway disease, bronchiectasis and fibro-cavitating disease, along with fungal and other respiratory infections [2]. The pathophysiology of PTLD will also be described in detail in the ERS Monograph entitled “The Challenge of Tuberculosis in the 21st Century”.

Link to published version: https://doi.org/10.1183/13993003.00950-2023